Sesen Bio (FRA:PCBK) Interest Expense : €0.00 Mil (TTM As of Dec. 2022)

View and export this data going back to 2016. Start your Free Trial

What is Sesen Bio Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Sesen Bio's interest expense for the three months ended in Dec. 2022 was € 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2022 was €0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Sesen Bio's Operating Income for the three months ended in Dec. 2022 was € -7.59 Mil. Sesen Bio's Interest Expense for the three months ended in Dec. 2022 was € 0.00 Mil. Sesen Bio has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Sesen Bio Interest Expense Historical Data

The historical data trend for Sesen Bio's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sesen Bio Interest Expense Chart

Sesen Bio Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Interest Expense

Get a 7-Day Free Trial

Sesen Bio Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Sesen Bio Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Sesen Bio (FRA:PCBK) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sesen Bio's Interest Expense for the three months ended in Dec. 2022 was €0.00 Mil. Its Operating Income for the three months ended in Dec. 2022 was €-7.59 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2022 was €0.00 Mil.

Sesen Bio's Interest Coverage for the quarter that ended in Dec. 2022 is calculated as

Sesen Bio had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Sesen Bio (FRA:PCBK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sesen Bio Inc (FRA:PCBK) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

245 First Street, Suite 1800, Cambridge, MA, USA, 02142

Website

https://www.sesenbio.com

Sesen Bio Inc is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The company's product candidate, Vicineum, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.

Sesen Bio (FRA:PCBK) Headlines

From GuruFocus

Pacific Continental Corp. (PCBK) CEO Hal Brown buys 5,000 Shares

By GuruFocus Research GuruFocus Editor • 10-15-2009

Pacific Continental Corp. (PCBK) CFO Michael Reynolds sells 1,650 Shares

By GuruFocus Research GuruFocus Editor • 02-22-2010

Pacific Continental Corp. (PCBK) President/COO Roger S Busse buys 1,000 Shares

By GuruFocus Research GuruFocus Editor • 10-15-2009

Pacific Continental Corp. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-04-2009